產(chǎn)品名稱 |
VMM5A |
商品貨號(hào) |
B167207 |
Organism |
Homo sapiens, human |
Tissue |
Melanoma, Lymph Node Metastasis |
Cell Type |
Melanocyte |
Product Format |
frozen |
Morphology |
Epithelial-like |
Culture Properties |
adherent |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
Melanoma, Stage IIIC; malignant |
Age |
81 |
Gender |
Male |
Ethnicity |
Caucasian |
Applications |
Drug screening
Development of targeted therapy
Development of combination therapy
Tumor vaccine development |
Storage Conditions |
liquid nitrogen vapor phase |
Images |
![ATCC CRL-3226 Cell Micrograph](/~/media/Attachments/Micrographs/Cell/CRL-3226%20Low%20High.ashx) |
Derivation |
Derived from tumors taken from tumor-involved lymph nodes from patients at the University of Virginia |
Clinical Data |
Primary Site: Right Posterior Shoulder; Metastatic Site: Lymph Node, Right Neck |
Antigen Expression |
Positives: High VEGF-R2, Low GP100, Tyrosinase, Low MAGE-A1, MMP-1 |
HLA Typing |
A2.1,A1101,B39,B44, BW4,BW6,C7(17)DR7, DR8,DR11,DQ2,DQ7 |
Comments |
NRAS: wt
CDKN2A: wt
BRAF Mutation: V600E
APC Mutation
PDGFRA Mutation: D842V
PTEN Mutation: R173H
more sensitive to BAY43-9006 (BRAF kinase inhibitor) and to
rapamycin (mTOR kinase inhibitor), compared to cell lines with wild-type B-Raf
|
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
Subculturing |
Volumes are for a T-75 flask; Adjust accordingly
- Remove and discard the cell culture medium from the flask.
- Rinse the cell monolayer with Dulbecco’s PBS without calcium or magnesium and remove.
- Add 3 to 4 ml of the trypsin-EDTA solution, rotate flask to rinse cell monolayer, remove trypsin solution, and incubate at 37oC.
- Once the cells appear to be detached, add 10 ml of complete growth medium with a pipette to
the cell suspension to inactivate the trypsin. Gently wash any remaining cells from the growth surface of the flask. Check the cells with the microscope to be sure that most (>95%) are single cells. If cell clusters are apparent, continue to disperse the cells with gentle pipetting.
- Subculture as necessary.
- Place the flask back into the incubator. Examine the culture the following day to ensure the cells have reattached and are actively growing.
- Repeat when cells reach confluence.
|
Cryopreservation |
Fetal bovine serum, 90%; DMSO, 10% |
Culture Conditions |
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2
), 5% |
STR Profile |
Amelogenin: X,Y
D5S818: 9
D7S820: 9,10
D13S317: 12
D16S539: 12
vWA: 16
TH01: 9.3
TPOX: 8,11
CSF1PO: 11 |
Sterility Tests |
Pass |
Name of Depositor |
Craig L. Slingluff, Jr. M.D. |
Passage History |
Unknown. 2 passages from 2003 frozen cell line stock, but it is not known how long the line was in culture after being established from tumor tissue obtained in 1992. |
Year of Origin |
1992 |
References |
Slingluff C, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother. 48:661-672, 2000. PubMed: 10752474
Molhoek K, et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Res. 68: (11), 2008. PubMed: 18519701
Molhoek K, et al. Comprehensive analysis of RTK activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 21(4): 274–284, 2011. PubMed: 21654344
Molhoek K, et al. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Trans. Med. 3(39): 2005. PubMed:16255777
|